Literature DB >> 16493206

Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey.

Peter J Barrett-Lee1, Heinz Ludwig, Gunnar Birgegård, Carsten Bokemeyer, Pere Gascón, Paris A Kosmidis, Maciej Krzakowski, Johan W R Nortier, Gail Kongable, Maurice Schneider, Dirk Schrijvers, Simon J Van Belle.   

Abstract

OBJECTIVES: To develop a hitherto unavailable risk factor model for accurately predicting anemia development in cancer patients before chemotherapy (CT) administration.
METHODS: 2,070 nonanemic patients from the European Cancer Anaemia Survey (ECAS) with hemoglobin (Hb) > or =12 g/dl at enrollment who received their first CT during ECAS and underwent at least two CT cycles were divided randomly into split half (SH) 1 and SH2 (n = 1,035 each). The model was developed on SH1 using logistic regression to simultaneously evaluate predictive factors, and was validated using SH2 and an additional similar subpopulation of 5,901 ECAS patients. Anemia risk values were assigned to the predictive factors and the sum of the predictive factors gave the total anemia risk score; lower-, higher-, and highest-risk cutoff points of the total anemia risk score were determined.
RESULTS: Variables ultimately identified as significant predictive factors for anemia were: lower initial Hb (< or =12.9 g/dl in females, and < or =13.4 g/dl in males); having lung or gynecologic cancer versus gastrointestinal (GI)/colorectal cancer; cancer at any other site versus GI/colorectal cancer; treatment with platinum CT, and female gender.
CONCLUSION: Using this evidence-based risk model, nonanemic patients who are at the highest risk of developing anemia prior to receiving CT can be identified clinically, allowing appropriate anemia management to be planned. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 16493206     DOI: 10.1159/000091675

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  15 in total

1.  The effect of chemotherapy-induced anemia on dose reduction and dose delay.

Authors:  Leila Family; Lanfang Xu; Hairong Xu; Kimberly Cannavale; Olivia Sattayapiwat; John H Page; Chet Bohac; Chun Chao
Journal:  Support Care Cancer       Date:  2016-05-11       Impact factor: 3.603

2.  Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy.

Authors:  Antonio Gómez; Mercedes Salgado; Manuel Valladares-Ayerbes; Mónica Jorge; Ana Carballo; Sonia Candamio; Pilar Izquierdo; Paula Peleteiro; Rafael López
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

3.  Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS).

Authors:  Pere Gascón; José Almenárez; Ángel Artal; Carlos Camps; José Luis Fírvida; Pilar Garrido; José Luis González Larriba; Joaquín Montalar
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

4.  Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.

Authors:  Maen Hussein; Marina Maglakelidze; Donald A Richards; Marielle Sabatini; Todd A Gersten; Keith Lerro; Ivan Sinielnikov; Alexander Spira; Yili Pritchett; Joyce M Antal; Rajesh Malik; J Thaddeus Beck
Journal:  Cancer Manag Res       Date:  2021-08-09       Impact factor: 3.989

Review 5.  Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.

Authors:  Anne Adams; Benjamin Scheckel; Anissa Habsaoui; Madhuri Haque; Kathrin Kuhr; Ina Monsef; Julia Bohlius; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2022-06-20

6.  Management of anemia and iron deficiency in a cancer center in France.

Authors:  Florence Laï-Tiong; Cloé Brami; Olivier Dubroeucq; Florian Scotté; Hervé Curé; Nicolas Jovenin
Journal:  Support Care Cancer       Date:  2015-08-08       Impact factor: 3.603

7.  Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.

Authors:  Lorenzo Gianni; Bernard F Cole; Ilaria Panzini; Raymond Snyder; Stig B Holmberg; Michael Byrne; Diana Crivellari; Marco Colleoni; Stefan Aebi; Edda Simoncini; Olivia Pagani; Monica Castiglione-Gertsch; Karen N Price; Aron Goldhirsch; Alan S Coates; Alberto Ravaioli
Journal:  Support Care Cancer       Date:  2007-07-13       Impact factor: 3.603

8.  Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy.

Authors:  Abolfazl Razzaghdoust; Bahram Mofid; Parvin Peyghambarlou
Journal:  Support Care Cancer       Date:  2019-04-16       Impact factor: 3.603

Review 9.  The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.

Authors:  Rahul Mhaskar; Hesborn Wao; Branko Miladinovic; Ambuj Kumar; Benjamin Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2016-02-04

10.  Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.

Authors:  J L Steegmann; J M Sánchez Torres; R Colomer; Á Vaz; J López; I Jalón; M Provencio; A González-Martín; M Pérez
Journal:  Clin Transl Oncol       Date:  2012-12-19       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.